GlassScriptPhysician profile
Eric Samuel Nadler
NPI 1134161243
$1,558,760.48
in general payments reported to CMS, 2019-2025
31 companies · $211K in 2025
The $211K reported for 2025 was more than what 99% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $275K · 2020: $147K · 2021: $234K · 2022: $234K · 2023: $219K · 2024: $238K · 2025: $211K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $443K · Consulting Fee: $108K · Travel and Lodging: $57K · Honoraria: $39K · Food and Beverage: $12K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $442,619.90 |
| Consulting Fee | $107,714.25 |
| Travel and Lodging | $56,915.98 |
| Honoraria | $38,825.00 |
| Food and Beverage | $11,888.29 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $10,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $462,631.09 | 2019-2025 | Tagrisso, Enhertu, Imfinzi |
| Genentech USA, INC. | $205,528.28 | 2019-2023 | |
| Jazz Pharmaceuticals INC. | $152,389.09 | 2020-2025 | |
| Mirati Therapeutics, INC. | $104,583.99 | 2023-2024 | Krazati |
| G1 Therapeutics, INC. | $98,127.38 | 2021-2023 | Cosela |
| Emd Serono, INC. | $92,872.03 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $78,087.73 | 2019-2025 | Keytruda |
| Regeneron Healthcare Solutions, INC. | $77,449.67 | 2021-2025 | Libtayo |
| Novocure INC. | $48,523.01 | 2022-2025 | Optune Lua (Novottf-200t) |
| Genzyme Corporation | $36,343.92 | 2021-2022 | |
| Pfizer INC. | $33,174.40 | 2020-2025 | |
| Lilly USA, LLC | $30,898.90 | 2021-2023 | Retevmo |
| Amgen INC. | $29,581.16 | 2023-2025 | Imdelltra (Amg757), Imdelltra (Amg 757), Lumakras |
| Daiichi Sankyo INC. | $28,133.71 | 2023-2025 | Datroway, Enhertu |
| Blueprint Medicines Corporation | $17,431.05 | 2020-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Catalyst Pharmaceuticals, INC. | $12,500.00 | 2023-2025 | Firdapse |
| Boehringer Ingelheim Pharmaceuticals, INC. | $10,360.73 | 2023-2025 | |
| Abbvie INC. | $9,622.33 | 2025 | |
| Seagen INC. | $8,000.00 | 2022 | |
| Eisai INC. | $6,465.00 | 2021-2022 | |
| Janssen Biotech, INC. | $4,304.09 | 2025 | Rybrevant |
| E.R. Squibb & Sons, L.L.C. | $4,150.75 | 2020-2024 | Opdivo |
| Aadi Bioscience, INC. | $3,500.00 | 2023 | Fyarro |
| Rigel Pharmaceuticals, INC. | $2,055.00 | 2025 | Gavreto |
| Takeda Pharmaceuticals U.S.A., INC. | $1,950.00 | 2024 | Alunbrig |
| Novartis Pharmaceuticals Corporation | $45.93 | 2022-2023 | |
| Gilead Sciences, INC. | $27.89 | 2021-2025 | Trodelvy |
| Pharmacosmos Therapeutics INC. | $23.35 | 2024 | Cosela |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Nadler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.